title: Effect of the duration between total body irradiation and stem cell infusion on the outcome of allogeneic transplantation with myeloablative conditioning.
abstract: OBJECTIVE
  Limited data are available on the effect of how cyclophosphamide (CY) and total body irradiation (TBI) are administered. We analyzed the effect of the interval from TBI to hematopoietic stem cell transplantation (HSCT) on the outcome of HSCT.
  
  
  METHODS
  Adult patients who underwent HSCT using myeloablative conditioning consisting of TBI and CY were retrospectively analyzed. They were divided into three groups according to the duration between the start of TBI and HSCT (Group A: 2-4 days, Group B: 5-8 days, Group C: 9-10 days).
  
  
  RESULTS
  Seventy-five adult patients were included. The 3-year overall survival rate was 56, 47, and 77% in Groups A, B, and C, respectively (P = 0.14). Similarly, there was no significant difference among the three groups with respect to progression-free survival (57, 47, and 72%, P = 0.17), relapse rate (32, 37, and 16%, P = 0.29), or non-relapse mortality (8, 14, and 12%, P = 0.81). In addition, we observed no significant difference among the three groups with respect to the incidence of grade II-IV acute graft-versus-host disease (GVHD) (31, 47, and 32%, respectively, P = 0.56) and that of chronic GVHD (23, 23, and 22%, respectively, P = 0.97).
  
  
  CONCLUSIONS
  Although recipient immune system at HSCT might be affected by the timing of TBI, the duration between the start of TBI and HSCT did not influence the outcome of HSCT using myeloablative conditioning with TBI and CY.
authors.forename: Yu
authors.initials: Y
authors.lastname: Akahoshi
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kako
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Nakano
authors.forename: Tomotaka
authors.initials: T
authors.lastname: Ugai
authors.forename: Hidenori
authors.initials: H
authors.lastname: Wada
authors.forename: Ryoko
authors.initials: R
authors.lastname: Yamasaki
authors.forename: Yuko
authors.initials: Y
authors.lastname: Ishihara
authors.forename: Koji
authors.initials: K
authors.lastname: Kawamura
authors.forename: Kana
authors.initials: K
authors.lastname: Sakamoto
authors.forename: Miki
authors.initials: M
authors.lastname: Sato
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ashizawa
authors.forename: Kiriko
authors.initials: K
authors.lastname: Terasako-Saito
authors.forename: Shun-ichi
authors.initials: S
authors.lastname: Kimura
authors.forename: Misato
authors.initials: M
authors.lastname: Kikuchi
authors.forename: Hideki
authors.initials: H
authors.lastname: Nakasone
authors.forename: Rie
authors.initials: R
authors.lastname: Yamazaki
authors.forename: Junya
authors.initials: J
authors.lastname: Kanda
authors.forename: Junji
authors.initials: J
authors.lastname: Nishida
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kanda
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D064591:Allografts; D002908:Chronic Disease; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality* / Q000628:therapy; D019337:Hematologic Neoplasms / Q000401:mortality* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D019172:Transplantation Conditioning; D014916:Whole-Body Irradiation
keywords: Cyclophosphamide; Graft-versus-host disease; Hematopoietic stem cell transplantation; Total body irradiation; Transplantation conditioning